1.
Human papillomavirus and cervical cancer
by Crosbie, Emma J, PhD
The Lancet (British edition), 2013, Vol.382 (9895), p.889-899
2.
A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines
by Schiller, John T
Vaccine, 2012, Vol.30 (5), p.F123-F138
3.
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
by Drolet, Mélanie, PhD
The Lancet infectious diseases, 2015, Vol.15 (5), p.565-580
4.
Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis
by D'Addario, Maddalena
Vaccine, 2017, Vol.35 (22), p.2892-2901
5.
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
by Kreimer, Aimée R, Dr
The lancet oncology, 2015, Vol.16 (7), p.775-786
6.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of t...
by Wheeler, Cosette M, Dr, Prof
The lancet oncology, 2012, Vol.13 (1), p.100-110
7.
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PA...
by Lehtinen, Matti, Prof
The lancet oncology, 2012, Vol.13 (1), p.89-99
8.
Human Papillomavirus Vaccine Introduction – The First Five Years
by Markowitz, Lauri E
Vaccine, 2012, Vol.30, p.F139-F148
9.
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomis...
by Wheeler, Cosette M, Prof
The Lancet infectious diseases, 2016, Vol.16 (10), p.1154-1168
10.
HPV single-dose vaccination: Impact potential, evidence base and further evaluation
by Stanley, Margaret
Vaccine, 2018, Vol.36 (32), p.4759-4760
11.
Planning for human papillomavirus (HPV) vaccination in sub-Saharan Africa: A modeling-based approach
by Tracy, J. Kathleen
Vaccine, 2014, Vol.32 (26), p.3316-3322
12.
Provider communication and HPV vaccination: The impact of recommendation quality
by Gilkey, Melissa B
Vaccine, 2016, Vol.34 (9), p.1187-1192
13.
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
by Youn, Jin Won
The lancet oncology, 2020, Vol.21 (12), p.1653-1660
14.
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind,...
by Skinner, S Rachel, PhD
The Lancet (British edition), 2014, Vol.384 (9961), p.2213-2227
15.
Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
by Kreimer, Aimée R
Vaccine, 2018, Vol.36 (32), p.4774-4782
16.
Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines
by Van Damme, Pierre
Vaccine, 2016, Vol.34 (6), p.757-761
17.
Status of HPV vaccine introduction and barriers to country uptake
by Gallagher, K.E
Vaccine, 2018, Vol.36 (32), p.4761-4767
18.
19.
Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity
by Pan, Huirong
Vaccine, 2017, Vol.35 (24), p.3222-3231
20.
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
by Muñoz, Nubia, Prof
The Lancet (British edition), 2009, Vol.373 (9679), p.1949-1957
